Peptides and sleep research, before the claims
Two peptides people often ask about in connection with sleep are DSIP, also listed as emideltide, and epitalon. Each has a guide that sets out what has been studied and what regulators concluded: DSIP and epitalon. This page shows where they stand legally. If you searched for “peptides for sleep”, this is the page for that research area.
- Evidence grade or review status for every compound
- Sources listed on every page
- US and sport status, dated
Two peptides people often ask about in connection with sleep are DSIP, also listed as emideltide, and epitalon. Each has a guide that sets out the studies and the regulators’ conclusions; this page makes no statement about effects. Neither is an FDA-approved medicine.
Compounds studied in this area
Grades describe the published evidence, not a promise of any effect.
DSIP
Delta sleep-inducing peptide, also listed as emideltide. By press reports, an FDA advisory committee voted against listing it for compounding in July 2026.
Read the DSIP guideEpitalon
A four-amino-acid peptide. An FDA advisory committee voted to recommend it for compounding in July 2026.
Longevity researchHow did FDA’s advisory committee vote on DSIP and epitalon?
What can’t we say yet about DSIP and epitalon?
Saying what we don't know is part of the evidence.
What DSIP or epitalon do in people. This page makes no statement about effects; the two guides set out the studies and their limits.
Are DSIP and epitalon FDA-approved medicines? US and sport status
As of November 2026. See the full tracker and the changelog.
| Compound | FDA approval | 503A compounding (2026) | WADA (2026 List) |
|---|---|---|---|
| DSIP | Not approved | Formerly FDA Category 2; nomination withdrawn (FDA list, current 22 Apr 2026); FDA advisory committee voted against listing (Jul, press-reported); not in the HHS policy | Not named; check with your anti-doping body |
| Epitalon | Not approved | FDA advisory committee voted for listing (Jul); HHS enforcement-discretion policy (Oct); no rule yet | Not named; S0 covers unapproved substances |
Worth knowing
Research use only
None of the compounds on this page is an FDA-approved medicine. Nothing on this page is medical advice or describes use in people.
What research use only meansNo doses, ever
We publish no doses, protocols, or cycles for people, on any page.
Why we publish no dosesHow we grade evidence
Grades follow study design: cell and animal studies (preclinical), small human studies, then controlled human trials, with approval tracked separately. A grade is not a promise of any effect.
Evidence gradesQuestions people ask
Did the FDA's advisory committee recommend DSIP?
No. By press reports, the compounding advisory committee voted against emideltide (DSIP) in July 2026, and the October HHS policy does not cover it.
Where is the evidence review?
In the DSIP guide and the epitalon guide. Each lists its sources and evidence tiers; this page shows legal status only.
Sources
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting page, 23–24 July 2026: agenda, voting questions and FDA briefing (no minutes posted as of 17 November 2026). www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, 28 Oct 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf
- World Anti-Doping Agency. Prohibited List 2026 (in force 1 January 2026) and 2027 (in force 1 January 2027). www.wada-ama.org/en/prohibited-list
- American Med Spa Association. FDA advisory committee recommends adding six of seven peptides to compounding list. News report of the vote counts, July 2026. www.americanmedspa.org/news/fda-advisory-committee-recommends-adding-six-of-seven-peptides-to-compounding-list/
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of 22 April 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- U.S. Department of Health and Human Services. Enforcement discretion policy, Appendix B: peptide identities and justifications, October 2026 (records the July 2026 committee outcome for each of the six peptides). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
Start with the evidence
Every page sourced and dated, including what the research does not show.
Open the research library